Fig. 1.

(A) Classification of the inhibitors used in development of the MRP4 models. Forty-five drugs were MRP4 inhibitors only and 31 drugs were BSEP inhibitors only, whereas 26 molecules inhibited both MRP4 and BSEP. (B) Of the compounds in (A), 14 MRP4 inhibitors were cholestatic, whereas only one BSEP inhibitor was identified as a cholestatic drug. Of the 26 compounds classified as both MRP4 and BSEP inhibitors, 15 (58%) were clinically identified as cholestatic.